BPC-157

Quick Verdict

The animal healing data here is extraordinary. Tendon, ligament, gut, nerve: BPC-157 accelerates repair across tissue types in rodent models more consistently than any other peptide we reviewed. Then you look for human evidence, and there is almost none. One small retrospective knee study with 16 patients. That gap between animal promise and human proof is wider here than anywhere else in this database. Sentiment is 82/100 across 10 tracked studies, driven almost entirely by community enthusiasm running years ahead of the science.

Evidence Quality

• Human trials: Weak (one small retrospective knee study showing 87.5% improvement in 16 patients, no RCTs)
• Animal evidence: Strong (extensive data across gut, tendon, bone, and nerve injury models)
• Community reports: Strong (large volume of consistent positive reports for injury recovery)
• Key uncertainty: Whether the angiogenesis mechanism that drives healing could also promote tumor growth in individuals with undiagnosed cancers.

What the Research Shows

BPC-157 fills a gap nothing else does: targeted tissue repair without the systemic effects of growth hormone or steroids. It is the most discussed peptide in community forums for injury recovery. Both oral and injectable routes exist in research protocols, with injectable being preferred for localized injury models in animal studies. The retrospective knee study found intra-articular injection significantly relieved knee pain in 87.5% of 16 patients surveyed.

Who Should Be Cautious

Anyone with a history of cancer or active malignancy should avoid BPC-157 due to its pro-angiogenic properties. Pregnant or nursing women have zero safety data to rely on.

What This Page Cannot Tell You

Correct human dosing has not been established. Every protocol circulating online is extrapolated from rat studies using body surface area conversions, which is an imprecise method at best.